Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Langer

Showing results (121-130 of 218) with videos related to

Pageof 22
Sort By:
The Journal of Pathology|November 1, 2021
Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patientsAchim Buck, Verena M Prade, Thomas Kunzke, et al.
Human Pathology|November 20, 2012
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcomeMarcus Bettstetter, Sabina Berezowska, Gisela Keller, et al.
Annals of Surgery|November 2, 2010
The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapyGüralp O Ceyhan, Florian Liebl, Matthias Maak, et al.
BMC Cancer|February 5, 2014
A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patientsSusanne Blank, Sivaramakrishna Rachakonda, Gisela Keller, et al.
Oncotarget|September 15, 2017
Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancerMonique Niklaus, Olivia Adams, Sabina Berezowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric CancerPaola Francica, Lluís Nisa, Daniel M Aebersold, et al.
International Journal of Molecular Sciences|October 10, 2018
Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma CellsFélice A Janser, Olivia Adams, Vanessa Bütler, et al.
Cancer Immunology, Immunotherapy : CII|March 15, 2017
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastasesBastian Dislich, Alexandra Stein, Christian A Seiler, et al.
Human Pathology|March 17, 2016
Impact of peritumoral and intratumoral budding in esophageal adenocarcinomasSvenja Thies, Lars Guldener, Julia Slotta-Huspenina, et al.
Cancer Research|June 17, 2005
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinomaBurkhard H A von Rahden, Hubert J Stein, Franziska Pühringer, et al.
Pageof 22

Showing results (121-130 of 218) with videos related to

Sort By:
Pageof 22
The Journal of Pathology|November 1, 2021
Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patientsAchim Buck, Verena M Prade, Thomas Kunzke, et al.
Human Pathology|November 20, 2012
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcomeMarcus Bettstetter, Sabina Berezowska, Gisela Keller, et al.
Annals of Surgery|November 2, 2010
The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapyGüralp O Ceyhan, Florian Liebl, Matthias Maak, et al.
BMC Cancer|February 5, 2014
A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patientsSusanne Blank, Sivaramakrishna Rachakonda, Gisela Keller, et al.
Oncotarget|September 15, 2017
Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancerMonique Niklaus, Olivia Adams, Sabina Berezowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric CancerPaola Francica, Lluís Nisa, Daniel M Aebersold, et al.
International Journal of Molecular Sciences|October 10, 2018
Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma CellsFélice A Janser, Olivia Adams, Vanessa Bütler, et al.
Cancer Immunology, Immunotherapy : CII|March 15, 2017
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastasesBastian Dislich, Alexandra Stein, Christian A Seiler, et al.
Human Pathology|March 17, 2016
Impact of peritumoral and intratumoral budding in esophageal adenocarcinomasSvenja Thies, Lars Guldener, Julia Slotta-Huspenina, et al.
Cancer Research|June 17, 2005
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinomaBurkhard H A von Rahden, Hubert J Stein, Franziska Pühringer, et al.
Pageof 22